Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Back to dashboard
Company Information
About this company
Key people
Ilya Rachman
Chairman of the Board, Chief Executive Officer
Gabriel Morris
President, Chief Financial Officer, Director
Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Helen C. Adams
Lead Independent Director
Nancy T. Chang
Director
Jane M. Buchan
Independent Director
Yekaterina Chudnovsky
Independent Director
Jason Hsu
Independent Director
Click to see more
Key facts
- Shares in issue71.61m
- EPICIMMX
- ISINUS45258H1068
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$977.23m
- Employees21
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.